Pretax income is the income that a company earns before paying income taxes. Ikena Oncology's pretax income for the
three
months ended in Mar. 2024 was $-16.12 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-70.23 Mil.
Ikena Oncology's pretax margin was %.
During the past 5 years, Ikena Oncology's highest Pretax Margin was -110.10%. The lowest was -1825.05%. And the median was -440.29%.
Ikena Oncology Pre-Tax Income Historical Data
The historical data trend for Ikena Oncology's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ikena Oncology's Pre-Tax Income
For the Biotechnology subindustry, Ikena Oncology's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ikena Oncology's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ikena Oncology's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Ikena Oncology's Pre-Tax Income falls into.
Ikena Oncology Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Ikena Oncology's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-70.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ikena Oncology (NAS:IKNA) Pre-Tax Income Explanation
Ikena Oncology's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 5 years, Ikena Oncology's highest Pretax Margin was -110.10%. The lowest was -1825.05%. And the median was -440.29%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ikena Oncology Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Ikena Oncology's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Ikena Oncology (Ikena Oncology) Business Description
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. its other product candidates are IK-175 and IK-595.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IKNA has been successfully added to your 